Brown: Risk Weighti...
Health Care: Drugs
Lexicon Pharmaceuticals Inc. (LXRX: NASDAQ)
$2.21 0.03 | 1.38%
05/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 2.21 |
| 52 Week High | 3.28 |
| 52 Week Low | 1.50 |
| Avg. Daily Vol. (Mil) | 0.77 |
| Beta (3 year) | 2.34 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,133.79 |
| Shares Out (Mil) | 513.03 |
| Float (Mil) | 120.67 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 11.00 |
| Current Ratio | 11.90 |
| LT Debt/ Equity | 0.09 |
| Total Debt / Equity | 0.10 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 986.76 |
| Price/Book | 4.68 |
| Price/Cash Flow | -8.60 |
| Per Share Data | |
| Earnings | -0.21 |
| Sales | 0.00 |
| Book Value | 0.47 |
| Cash Flow | -0.26 |
| Business Summary | |
|---|---|
| Lexicon Pharmaceuticals, Inc., operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. | |
| General Information | |
| 8800 Technology Forest Place
The Woodlands, TX 77381 |
|
| www.lexicon-genetics.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 230 | |
| CEO: Dr. Arthur T. Sands,M.D. | |
| Short Interest | |
| Current Month (Mil) | 9.07 |
| Previous Month (Mil) | 8.64 |
| Short Interest Ratio (Days) | 10.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -39.20 |
| Return on Investments | -51.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with LXRX
- Portfolio NameUser Type
- UserMy stocks
- ContributorStocks With Big Insider Buy...
- UserMy SP portfolio
- UserWatch
- ContributorStocks Under-$10 Setting Up...
- Contributor22 Biopharma Stocks With Br...
- ContributorStocks Under-$10 Moving Hig...
- Contributor8 Health Care Stocks With R...
- Userhpats Portfolio 1
- Userpkc89
Latest LXRX Headlines from TheStreet
- Lexicon Pharma Falls on Concerns Raised by Merck-Pfizer Diabetes Partnership 04.29.13 | 11:04 am
- 8 Stocks Under $5 Seeing Institutional And Insider Buying 04.02.13 | 03:04 pm
- 7 Biotechnology Stocks With Insider Buying Activity 03.20.13 | 10:03 am
- 10 Stocks Insiders And Hedge Funds Think Will Go Higher 03.11.13 | 01:03 pm
- Still Bullish on BioMarin, Lexicon Pharma 11.07.12 | 11:11 am
- 5 Stocks Insiders Love Right Now 10.31.12 | 02:10 pm
- Lexicon Pharma: Blockbuster Potential From A Diabetes Drug 10.16.12 | 06:10 am
- Lexicon Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript) 09.11.12 | 02:09 pm
- Lexicon's CEO Presents At Wedbush PacGrow 2012 Life Sciences Management Access Conference (Transcript) 08.14.12 | 05:08 pm
- Lexicon Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript 07.31.12 | 02:07 pm
Press Releases for LXRX
- Lexicon To Present At The Bank Of America Merrill Lynch Healthcare Conference - PR Newswire 05.13.13 | 06:05 am
- Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial - PR Newswire 05.10.13 | 06:05 am
- Lexicon To Report First Quarter Financial Results On May 10, 2013 - PR Newswire 05.03.13 | 06:05 am
- Lexicon To Present At The Needham Healthcare Conference - PR Newswire 04.25.13 | 06:04 am
- Lexicon To Present At The Cowen Healthcare Conference - PR Newswire 03.01.13 | 06:03 am
- Lexicon To Present At The RBC Capital Markets Healthcare Conference - PR Newswire 02.25.13 | 06:02 am
- Lexicon To Report Fourth Quarter And Year End 2012 Financial Results On February 21, 2013 - PR Newswire 02.18.13 | 06:02 am
- Lexicon To Present At The BIO CEO & Investor Conference - PR Newswire 02.06.13 | 06:02 am
- Lexicon To Present At The J.P. Morgan Healthcare Conference - PR Newswire 01.03.13 | 06:01 am
- Lexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA - PR Newswire 12.17.12 | 06:12 am
Partner Headlines for LXRX
- Investors Wait On Developments For Lexicon Pharmaceuticals - Seeking Alpha 01.03.13 | 08:01 am
- Three Compelling Biopharma Stocks For 2013 - Seeking Alpha 12.26.12 | 09:12 am
- Top 5 Stocks With Insider Buys Filed During The Week Ending October 26 - Seeking Alpha 10.28.12 | 07:10 am
- Lexicon Prices 17.5M Shares At $2.25 per Share - Benzinga 10.18.12 | 09:10 am
- Will Lexicon Pharmaceuticals's Top Institutional Shareholders DOUBLE DOWN on These Hot Catalysts? - Wall St. Cheat Sheet 06.29.12 | 12:06 pm
- Healthcare Biz Review: Icahn SUES Forest, eHealth's EXCELLENT News - Wall St. Cheat Sheet 06.29.12 | 09:06 am
- Comcast's OLYMPIC Strategy and 4 Buzzing Stocks to Know Friday - Wall St. Cheat Sheet 06.29.12 | 09:06 am
- Apollo Group SPIKES 10% to Lead These 5 NASDAQ Top Percentage Winners - Wall St. Cheat Sheet 06.27.12 | 10:06 am
- Wall St. Watchdog Stock Analysts Reiterated Their Ratings of These 3 Shares Today - Wall St. Cheat Sheet 06.26.12 | 03:06 am
- Lexicon UPBEAT Regarding Drug Trial and 4 HOT Analyst Alerts - Wall St. Cheat Sheet 06.26.12 | 02:06 am
